🇺🇸 FDA
Patent

US 9980976

Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists

granted A61KA61K31/407A61K31/4164

Quick answer

US patent 9980976 (Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists) held by Northwestern University expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Northwestern University
Grant date
Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/407, A61K31/4164, A61K31/429, A61K31/436